de Recherche et d’Innovation
en Cybersécurité et Société
Katzman, M. A.; Bleau, P.; Blier, P.; Chokka, P.; Kjernisted, K.; Ameringen, M. Van; Antony, M. M.; Bouchard, S.; Brunet, A.; Flament, M.; Rabheru, K.; Grigoriadis, S.; Richter, P. M. A.; Mendlowitz, S.; O'Connor, K.; Robichaud, M.; Walker, J. R.; Asmundson, G.; Klassen, L. R.; Lam, R. W.; McIntyre, R. S.; Szpindel, I.
Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders Article de journal
Dans: BMC Psychiatry, vol. 14, no SUPPL.1, 2014, ISSN: 1471244X (ISSN), (Publisher: BioMed Central Ltd.).
Résumé | Liens | BibTeX | Étiquettes: agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine
@article{katzman_canadian_2014,
title = {Canadian clinical practice guidelines for the management of anxiety, posttraumatic stress and obsessive-compulsive disorders},
author = {M. A. Katzman and P. Bleau and P. Blier and P. Chokka and K. Kjernisted and M. Van Ameringen and M. M. Antony and S. Bouchard and A. Brunet and M. Flament and K. Rabheru and S. Grigoriadis and P. M. A. Richter and S. Mendlowitz and K. O'Connor and M. Robichaud and J. R. Walker and G. Asmundson and L. R. Klassen and R. W. Lam and R. S. McIntyre and I. Szpindel},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-84903778611&doi=10.1186%2f1471-244X-14-S1-S1&partnerID=40&md5=4787fc6f97c204c1428770a5e4a57a00},
doi = {10.1186/1471-244X-14-S1-S1},
issn = {1471244X (ISSN)},
year = {2014},
date = {2014-01-01},
journal = {BMC Psychiatry},
volume = {14},
number = {SUPPL.1},
abstract = {Background: Anxiety and related disorders are among the most common mental disorders, with lifetime prevalence reportedly as high as 31%. Unfortunately, anxiety disorders are under-diagnosed and under-treated.Methods: These guidelines were developed by Canadian experts in anxiety and related disorders through a consensus process. Data on the epidemiology, diagnosis, and treatment (psychological and pharmacological) were obtained through MEDLINE, PsycINFO, and manual searches (1980-2012). Treatment strategies were rated on strength of evidence, and a clinical recommendation for each intervention was made, based on global impression of efficacy, effectiveness, and side effects, using a modified version of the periodic health examination guidelines.Results: These guidelines are presented in 10 sections, including an introduction, principles of diagnosis and management, six sections (Sections 3 through 8) on the specific anxiety-related disorders (panic disorder, agoraphobia, specific phobia, social anxiety disorder, generalized anxiety disorder, obsessive-compulsive disorder, and posttraumatic stress disorder), and two additional sections on special populations (children/adolescents, pregnant/lactating women, and the elderly) and clinical issues in patients with comorbid conditions.Conclusions: Anxiety and related disorders are very common in clinical practice, and frequently comorbid with other psychiatric and medical conditions. Optimal management requires a good understanding of the efficacy and side effect profiles of pharmacological and psychological treatments. © 2014 Katzman et al.},
note = {Publisher: BioMed Central Ltd.},
keywords = {agoraphobia, Anxiety disorder, Anxiety Disorders, benzodiazepine derivative, buspirone, Canada, clinical trial, clomipramine, comorbidity, duloxetine, escitalopram, fluoxetine, fluvoxamine, fluvoxamine maleate, GAD, generalized anxiety disorder, guidelines, human, Humans, obsessive compulsive disorder, Obsessive-Compulsive Disorder, OCD, panic, Panic Disorder, paroxetine, periodic medical examination, pharmacotherapy, Post-Traumatic, posttraumatic stress disorder, practice guideline, Practice Guidelines as Topic, psychotherapy, PTSD, recommendations, review, sertraline, social anxiety disorder, social phobia, special populations, Specific phobia, Stress Disorders, venlafaxine},
pubstate = {published},
tppubtype = {article}
}
Savard, J.; Laberge, B.; Gauthier, J. G.; Founder, J. -P.; Bouchard, S.; Baril, J. -G.; Bergeron, M. G.
Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation Article de journal
Dans: Cognitive Therapy and Research, vol. 22, no 1, p. 21–46, 1998, ISSN: 01475916 (ISSN), (Publisher: Springer New York LLC).
Résumé | Liens | BibTeX | Étiquettes: adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome
@article{savard_combination_1998,
title = {Combination of fluoxetine and cognitive therapy for the treatment of major depression among people with HIV infection: A time-series analysis investigation},
author = {J. Savard and B. Laberge and J. G. Gauthier and J. -P. Founder and S. Bouchard and J. -G. Baril and M. G. Bergeron},
url = {https://www.scopus.com/inward/record.uri?eid=2-s2.0-0031957952&doi=10.1023%2fA%3a1018759802082&partnerID=40&md5=bf7c480d95e52b00202cfcb1f34af74f},
doi = {10.1023/A:1018759802082},
issn = {01475916 (ISSN)},
year = {1998},
date = {1998-01-01},
journal = {Cognitive Therapy and Research},
volume = {22},
number = {1},
pages = {21–46},
abstract = {The aim of the present study was to evaluate the efficacy of a combined treatment of fluoxetine and cognitive therapy for the treatment of major depression in HIV-infected patients. Six HIV-seropositive patients with major depression participated in this study using a multiple-baseline experimental design with follow-up and direct replications. Results of time-series intervention analyses suggest that the combination of fluoxetine and cognitive therapy can provide an effective treatment for major depression in HIV illness that may be more effective than fluoxetine alone. However, relapse rates and follow-up results raise some concerns about the long-term efficacy of the combined treatment as administered in this study. Cooccurence of a personality disorder is suggested as an explanatory hypothesis.},
note = {Publisher: Springer New York LLC},
keywords = {adult, AIDS, alcoholism, article, clinical article, clinical trial, clonazepam, cognitive therapy, comorbidity, demography, Depression, disease association, drug efficacy, female, fluoxetine, HIV, human, Human immunodeficiency virus infection, male, patient attitude, personality disorder, relapse, Treatment, treatment outcome},
pubstate = {published},
tppubtype = {article}
}